REGULATORY

MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer

May 28, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A subcommittee of the Central Social Insurance Medical Council (Chuikyo) will issue an interim report this summer on the planned rollout of cost-effective assessments for Japan’s drug and medical device pricing system, with an eye to seeking FY2016 budgets to…

To read the full story

FY2016 Drug Pricing Reform
August 18, 2015
HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
Pay Heed to Company Burdens for Cost-Effective Evaluations, Kamoya Tells Chuikyo
May 28, 2015

REGULATORY

US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
Kampo Industry Calls for Predictable Drug Pricing to Support Stable Supply
June 23, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…